翻訳と辞書 |
Axovant Sciences : ウィキペディア英語版 | Axovant Sciences Axovant Sciences, Ltd. is a Bermuda-based public company which develops pharmaceutical drugs.〔 The company's sole product in development as of 2015 was RVT-101, an add-on treatment in combination with donepezil for Alzheimer's disease—associated dementia.〔〔 Axovant licensed this drug candidate (developed as SB-742457) from GlaxoSmithKline in December 2014 for , milestone payments if the drug reaches market, and a proportion of sales.〔〔 The company's initial public offering in 2015 was thought at the time to be the highest grossing ever in the biotechnology industry.〔 Axovant trades on the New York Stock Exchange under the symbol "AXON".〔 The founder of Axovant is Vivek Ramaswamy, a former hedge-fund manager.〔〔 Ramaswamy had previously founded Roivant Sciences in May 2014, then created Axovant as a spin-off company from Roivant in October.〔〔 As of 2015, Roivant retained an 80% ownership stake in Axovant.〔 ==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Axovant Sciences」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|